The Comparison of Brand-Name and Generic Formulations of Venlafaxine
- 1 April 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 36 (2), 269-272
- https://doi.org/10.1097/ftd.0000000000000008
Abstract
Venlafaxine (VEN) is a widely used antidepressant drug, which is available in both brand-name and generic formulations. Bioequivalence studies indicate some pharmacokinetic variability. However, naturalistic therapeutic drug monitoring studies of different generic formulations are lacking. In 2010, inpatients of the Department of Psychiatry, Psychosomatics, and Psychotherapy, University Hospital of Würzburg, were treated with either slow-release brand-name VEN (Trevilor) or slow-release generic VEN (Venlafaxin Hexal) depending on the respective inpatient ward. Routine therapeutic drug monitoring analyses of both groups were compared after matching samples regarding dose of VEN, gender, age, smoking habits, and evaluation of co-medication. Both groups did not differ in mean values of VEN, O-desmethyl-VEN (ODV), VEN + ODV serum concentrations, and ODV/VEN ratio. No difference in dose-corrected serum concentrations between generic and brand-name VEN was revealed for males, females, smokers, or nonsmokers. In both groups, Spearman Rho correlation between VEN dose and VEN + ODV serum concentration was moderate but significant (P < 0.001; generic: r = 0.554; brand name: r = 0.668). Within the generic subgroup, females had a significantly higher dose-corrected serum concentration of VEN (U test, P < 0.05), whereas within brand name, no gender influence was detected. Spearman Rho correlation of age and dose-corrected ODV (P < 0.05) and VEN + ODV (P < 0.05) was significant only in the generic group. In the brand-name sample, smokers had significantly lower dose-corrected serum concentrations of ODV (U test, P < 0.01) and VEN + ODV (P < 0.01). In the generic group, smoking habit was without any influence. No differences in serum concentrations in dependence of either VEN formulations suggest a safe and efficient treatment of patients using the evaluated generic VEN. However, differences within one formulation regarding gender, age, and smoking status suggest variability of serum concentrations and thus could endanger safety and efficacy of drug use.Keywords
This publication has 22 references indexed in Scilit:
- Gender Differences in the Pharmacokinetics of Oral DrugsPharmacology & Pharmacy, 2011
- Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed statesClinical Therapeutics, 2010
- Switching from Brand‐Name to Generic Psychotropic Medications: A Literature ReviewCNS Neuroscience & Therapeutics, 2010
- Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switchingInternational Clinical Psychopharmacology, 2010
- Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: Four open-label, randomized crossover trials in healthy volunteersClinical Therapeutics, 2009
- Comparison of Pharmacokinetic Profiles of Brand-Name and Generic Formulations of Citalopram and VenlafaxinePublished by Physicians Postgraduate Press, Inc ,2009
- Rapid high‐performance liquid chromatography–tandem mass spectrometry method for simultaneous measurement of venlafaxine and O‐desmethylvenlafaxine in human plasma and its application in comparative bioavailability studyBiomedical Chromatography, 2009
- CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxineJournal of Clinical Pharmacy & Therapeutics, 2006
- Therapeutic Drug Monitoring of Psychotropic DrugsTherapeutic Drug Monitoring, 2004
- The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugsClinical Therapeutics, 2003